A trial stimulation system includes a trial electrical stimulator. Additionally, systems for securing a disposable trial stimulator to the body of a patient are described, which may function to improve the durability of the system during the trial period and reduce the risk of damage or malfunction to the system due to lead/electrode dislocation and/or off-label uses like showering or bathing with the trial stimulator still secured to the body.

The invention refers to a device for inhibiting the neural activity of a carotid sinus nerve (CSN) or carotid body of a subject, the device comprising: one or more transducers configured to apply a signal to the CSN or associated carotid body of the subject, optionally at least two such transducers; and a controller coupled to the one or more transducers, the controller controlling the signal to be applied by the one or more transducers, such that the signal inhibits the neural activity of the CSN or carotid body to produce a physiological response in the subject, wherein the physiological response is one or more of the group consisting of: an increase in insulin sensitivity in the subject, an increase in glucose tolerance in the subject, a decrease in (fasting) plasma glucose concentration in the subject, a reduction in subcutaneous fat content in the subject, and a reduction in obesity in the subject.

The present invention provides a method for treating diabetes and nonalcoholic fatty liver disease (NAFLD), associated condition or disorder thereof, or symptoms thereof suffered by a subject such as a mammal (e.g. a human patient or a pet), comprising (1) placing one or more electrodes within a target blood vessel of the subject and against the target blood vessel wall, wherein the target blood vessel includes the celiac artery and/or a segment of the abdominal aorta terminated at its junction with the celiac artery; (2) adhering a surface electrode on an external surface such as skin of the subject; and (3) releasing a therapeutically effective amount of radiofrequency energy through the one or more electrodes to nearby tissues, so as to increase the temperature of the nearby tissues and induce a thermal alteration of the nearby tissues.

The present disclosure relates to methods, devices and systems used for the treatment of medical disorders via stimulation of the superficial elements of the trigeminal nerve. More specifically, cutaneous methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, infraorbital, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein.

Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

A system for percutaneously applying electrical stimulation to target nerve tissue to treat a patient having peripheral neuropathy includes a percutaneous electrode assembly, a power supply, and a pulse generator electrically coupled to the percutaneous electrode assembly and the power supply, the pulse generator configured to deliver electrical stimulation to the target nerve tissue via the percutaneous electrode assembly at a level that initiates vasodilation of vasculature within or adjacent the target nerve tissue, where the vasculature is responsible for perfusing the target nerve tissue and the electrical stimulation is delivered with a carrier frequency in the range of 25 kHz to 500 kHz.

Neuromodulation catheter systems with controlled irrigation capabilities and methods for using such systems are disclosed herein. One such method includes, for example, positioning an irrigated neuromodulation catheter at a treatment site within a renal blood vessel of a human patient, delivering neuromodulation energy at the treatment site, and delivering irrigation fluid to the treatment site having characteristics coordinated with the delivered energy. The characteristics can be adjusted to maintain an energy delivery element and/or tissue of the blood vessel at a constant temperature as power is increased. The method can further include monitoring at least one parameter of the tissue and/or of the energy delivery element, and adjusting the neuromodulation energy and/or the characteristics of the irrigation fluid if the at least one parameter falls outside of a treatment range of values.

Disclosed herein are methods, devices, and systems for evaluation, diagnosis, prevention, and treatment of peripheral neuropathies.

A trial stimulation system includes a trial electrical stimulator. Additionally, systems for securing a disposable trial stimulator to the body of a patient are described, which may function to improve the durability of the system during the trial period and reduce the risk of damage or malfunction to the system due to lead/electrode dislocation and/or off-label uses like showering or bathing with the trial stimulator still secured to the body.

A cuff is described for a target anatomic feature within a body, along with a system for utilizing the cuff. The cuff includes a band defining a circumferential opening extending along a length of the band; and a pair of engagement surfaces defined by or affixed to the cuff, the engagement surfaces structured for application of a spreading force to be distributed continuously along a portion of the circumferential opening, thereby increasing the circumferential opening and expanding the cuff for a closed configuration to an open configuration sized for placement of the cuff. The cuff is structured to remain in the closed configuration in the absence of the spreading force and automatically return to the closed configuration after removal of the spreading force.